JP2015512432A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512432A5
JP2015512432A5 JP2015503847A JP2015503847A JP2015512432A5 JP 2015512432 A5 JP2015512432 A5 JP 2015512432A5 JP 2015503847 A JP2015503847 A JP 2015503847A JP 2015503847 A JP2015503847 A JP 2015503847A JP 2015512432 A5 JP2015512432 A5 JP 2015512432A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
eosinophilic
chloride
composition according
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015503847A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512432A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/056864 external-priority patent/WO2013149986A1/en
Publication of JP2015512432A publication Critical patent/JP2015512432A/ja
Publication of JP2015512432A5 publication Critical patent/JP2015512432A5/ja
Pending legal-status Critical Current

Links

JP2015503847A 2012-04-03 2013-04-02 Ccr3阻害薬の使用 Pending JP2015512432A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12162937 2012-04-03
EP12162937.2 2012-04-03
PCT/EP2013/056864 WO2013149986A1 (en) 2012-04-03 2013-04-02 Use of ccr3-inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017246173A Division JP2018080183A (ja) 2012-04-03 2017-12-22 Ccr3阻害薬の使用

Publications (2)

Publication Number Publication Date
JP2015512432A JP2015512432A (ja) 2015-04-27
JP2015512432A5 true JP2015512432A5 (enExample) 2016-06-02

Family

ID=48040249

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015503847A Pending JP2015512432A (ja) 2012-04-03 2013-04-02 Ccr3阻害薬の使用
JP2017246173A Withdrawn JP2018080183A (ja) 2012-04-03 2017-12-22 Ccr3阻害薬の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017246173A Withdrawn JP2018080183A (ja) 2012-04-03 2017-12-22 Ccr3阻害薬の使用

Country Status (28)

Country Link
US (5) US20130261153A1 (enExample)
EP (3) EP4389217A3 (enExample)
JP (2) JP2015512432A (enExample)
KR (5) KR20210063481A (enExample)
CN (2) CN104220073A (enExample)
AU (1) AU2013245027B2 (enExample)
BR (1) BR112014023795B1 (enExample)
CA (1) CA2869269C (enExample)
CL (1) CL2014002523A1 (enExample)
CY (1) CY1123222T1 (enExample)
DK (1) DK2833884T3 (enExample)
EA (1) EA032263B1 (enExample)
ES (2) ES2987267T3 (enExample)
HR (1) HRP20201165T1 (enExample)
HU (1) HUE051648T2 (enExample)
IL (1) IL234262A (enExample)
IN (1) IN2014DN06989A (enExample)
LT (1) LT2833884T (enExample)
MX (1) MX2014011786A (enExample)
NZ (1) NZ628882A (enExample)
PH (1) PH12014502239A1 (enExample)
PL (1) PL2833884T3 (enExample)
PT (1) PT2833884T (enExample)
RS (1) RS60665B1 (enExample)
SI (1) SI2833884T1 (enExample)
SM (1) SMT202000499T1 (enExample)
WO (1) WO2013149986A1 (enExample)
ZA (1) ZA201406082B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US11045284B2 (en) 2016-11-24 2021-06-29 Kirishima Seiko Co., Ltd. Dental brace and method for attaching dental brace
NZ757769A (en) * 2017-04-05 2025-10-31 Alkahest Inc Methods and compositions for treating retina-associated disease using ccr3-inhibitors
WO2018187503A1 (en) 2017-04-05 2018-10-11 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
JP2020536929A (ja) * 2017-10-13 2020-12-17 アルカヘスト,インコーポレイテッド Ccr3阻害剤を用いた、そう痒症、乾皮症、及び関連疾患を治療するための方法及び組成物
AU2019271122A1 (en) 2018-05-15 2020-11-12 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase
CA3111433A1 (en) * 2018-09-26 2020-04-02 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
JP2023529719A (ja) * 2020-06-11 2023-07-11 アルカヘスト,インコーポレイテッド Ccr3阻害剤を使用した網膜関連疾患の転帰改善方法
US11957671B2 (en) 2021-11-01 2024-04-16 Alkahest, Inc. Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
IL151499A0 (en) * 2000-03-03 2003-04-10 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
WO2006083390A2 (en) * 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
US8008092B2 (en) * 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US8778616B2 (en) * 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Similar Documents

Publication Publication Date Title
JP2015512432A5 (enExample)
EP4389217A3 (en) Use of ccr3-inhibitors
JP2016515561A5 (enExample)
JP2014515351A5 (enExample)
JP2017518302A5 (enExample)
JP2014097964A5 (enExample)
JP2015537020A5 (enExample)
JP2016506935A5 (enExample)
JP2016531126A5 (enExample)
JP2016534063A5 (enExample)
JP2015508103A5 (enExample)
JP2016040288A5 (enExample)
JP2019515908A5 (enExample)
JP2016510326A5 (enExample)
JP2014505107A5 (enExample)
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
EP3069720A8 (en) Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
JP2015509075A5 (enExample)
JP2019535723A5 (enExample)
JP2019505529A5 (enExample)
JP2017503014A5 (enExample)
JP2013523846A5 (enExample)
RU2489433C9 (ru) Производное циклобутилпурина, агент, активирующий ангиогенез, агент, активирующий образование просвета, агент, активирующий рост нейронов, и лекарственное средство
CN110139863A (zh) 作为雌激素受体降解剂的吲哚并取代哌啶类化合物
JP2018524306A5 (enExample)